Trastuzumab deruxtecan in advanced breast cancer patients with brain metastases or leptomeningeal metastases
Year: 2025
Type: article
Abstract: •Trastuzumab deruxtecan showed superior intracranial overall response rate (ORR) and median progression-free survival (mPFS) than controls in both stable and active brain metastases.•DEBBRAH, TUXEDO-1, and DESTINY-Breast 12 confirm durable intracranial activity in brain metastases with trastuzumab deruxtecan.•Real-world ROSET-BM data reported median overall survival (OS, 27.0 months) and mPFS (14.6 months) in active BM, reinforcing T-DXd efficacy.•In leptomeningeal metastases (LM) cohorts, T-DXd achieved clinical benefit rate (71.4-100%), mOS (10.4-13.3 months), and mPFS (8.9-17.5 months) across studies.•For active BM, local intervention plus T-DXd (or tucatinib combination) is recommended based on efficacy stratification.
Source: Cancer Pathogenesis and Therapy
Authors: Jinsong Liu, Liuliu Quan, Die Sang, Xiao Guan, Min Dou, Jian Yue, Peng Yuan
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,100
Award: G4281327215
OpenAlex ID: W4410487303